ca Prevalence and Determinants of Glucose Intolerance in a Dutch Caucasian Population: The Hoorn Study By care.diabetesjournals.org Published On :: 1995-09-01 Johanna M MooySep 1, 1995; 18:1270-1273Short Report Full Article
ca Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association By care.diabetesjournals.org Published On :: 2015-10-01 Richard A. InselOct 1, 2015; 38:1964-1974Scientific Statement Full Article
ca Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association By care.diabetesjournals.org Published On :: 2016-12-01 Deborah Young-HymanDec 1, 2016; 39:2126-2140Psychosocial Research and Care in Diabetes Full Article
ca Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood Glucose By care.diabetesjournals.org Published On :: 1987-09-01 William L ClarkeSep 1, 1987; 10:622-628Technical Article Full Article
ca Metabolic Implications of Body Fat Distribution By care.diabetesjournals.org Published On :: 1991-12-01 Per BjörntorpDec 1, 1991; 14:1132-1143Diet and Diabetes Full Article
ca Diabetes and Glucose Tolerance as Risk Factors for Cardiovascular Disease: The Framingham Study By care.diabetesjournals.org Published On :: 1979-03-01 W B KannelMar 1, 1979; 2:120-126Proceedings of the Kroc Foundation International Conference on Epidemiology of Diabetes and its Macrovascular Complications Full Article
ca Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society By care.diabetesjournals.org Published On :: 2013-05-01 Elizabeth R. SeaquistMay 1, 2013; 36:1384-1395Scientific Statement Full Article
ca Latin American business leaders optimistic about region’s post-pandemic economy By www.upi.com Published On :: Wed, 06 May 2020 18:44:51 -0400 Despite worrying economic projections, business leaders in Latin America remain optimistic about post-pandemic economy. Full Article
ca Gas leak at India chemical plant kills 8, sickens hundreds By www.upi.com Published On :: Thu, 07 May 2020 03:34:34 -0400 At least eight people died and hundreds were hospitalized after toxic gas leaked from a chemical factory in southern India early Thursday, officials said. Full Article
ca Australian Cardinal George Pell knew of child abuse, report says By www.upi.com Published On :: Thu, 07 May 2020 07:21:04 -0400 Pell, a former Vatican treasurer, was aware of child abuse being committed by clergy by 1973, contrary to his long-held assertions that he knew nothing about the accusations. Full Article
ca Digitizing financial services key to Africa's post-pandemic growth, experts say By www.upi.com Published On :: Thu, 07 May 2020 16:18:10 -0400 As the COVID-19 pandemic begins to take root in Africa, experts say that digitizing financial services could help keep the continent safe Full Article
ca South Korea sees new cluster of COVID-19 cases tied to nightclubs By www.upi.com Published On :: Fri, 08 May 2020 07:16:30 -0400 Just days after South Korea loosened its social distancing guidelines, a new COVID-19 cluster of infections has sprung up in the capital city of Seoul tied to several nightclubs. Full Article
ca Coast Guard names Rear Adm. Melissa Bert as first female judge advocate general By www.upi.com Published On :: Mon, 04 May 2020 16:56:44 -0400 The U.S. Coast Guard named Rear Adm. Melissa Bert as its first female judge advocate and chief counsel, its top legal position. Full Article
ca Navy breaks ground on laser weapons test lab in California By www.upi.com Published On :: Thu, 07 May 2020 18:29:45 -0400 Navy leaders and private contractors broke ground this week on what will become the fleet's only dedicated facility to test, fire and evaluate complete laser weapon systems in a maritime environment. Full Article
ca Boeing awarded $128.5M modification to GMD missile upgrade contract By www.upi.com Published On :: Thu, 07 May 2020 19:36:45 -0400 Boeing was awarded a $128.5 million modification to its Ground-based Midcourse Defense development and sustainment contract Thursday, according to the Pentagon. Full Article
ca Type 1 Diabetes Mellitus and Cardiovascular Disease: A Scientific Statement From the American Heart Association and American Diabetes Association By care.diabetesjournals.org Published On :: 2014-10-01 Sarah D. de FerrantiOct 1, 2014; 37:2843-2863Scientific Statement Full Article
ca Diabetes and Aging: Unique Considerations and Goals of Care By care.diabetesjournals.org Published On :: 2017-04-01 Rita R. KalyaniApr 1, 2017; 40:440-443Emerging Science and Concepts for Management of Diabetes and Aging Full Article
ca Effect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One-Year Results of the PREDIMED-Plus Trial By care.diabetesjournals.org Published On :: 2019-05-01 Jordi Salas-SalvadóMay 1, 2019; 42:777-788Continuing Evolution of Nutritional Therapy for Diabetes Full Article
ca Professional Practice Committee: Standards of Medical Care in Diabetes--2019 By care.diabetesjournals.org Published On :: 2019-01-01 Jan 1, 2019; 42:S3-S3Professional Practice Committee Full Article
ca HbA1c Levels Are Significantly Lower in Early and Late Pregnancy By care.diabetesjournals.org Published On :: 2004-05-01 Lene R. NielsenMay 1, 2004; 27:1200-1201Brief Reports Full Article
ca Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association By care.diabetesjournals.org Published On :: 2015-10-01 Richard A. InselOct 1, 2015; 38:1964-1974Scientific Statement Full Article
ca Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study By care.diabetesjournals.org Published On :: 2016-10-01 Khalid A. JadoonOct 1, 2016; 39:1777-1786Emerging Technologies and Therapeutics Full Article
ca PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes By care.diabetesjournals.org Published On :: 2019-09-01 Vanita R. ArodaSep 1, 2019; 42:1724-1732Emerging Therapies: Drugs and Regimens Full Article
ca Disclosures: Standards of Medical Care in Diabetes--2020 By care.diabetesjournals.org Published On :: 2020-01-01 Jan 1, 2020; 43:S205-S206Disclosures Full Article
ca Impact of Fat, Protein, and Glycemic Index on Postprandial Glucose Control in Type 1 Diabetes: Implications for Intensive Diabetes Management in the Continuous Glucose Monitoring Era By care.diabetesjournals.org Published On :: 2015-06-01 Kirstine J. BellJun 1, 2015; 38:1008-1015Type 1 Diabetes at a Crossroads Full Article
ca The Pathophysiology of Hyperglycemia in Older Adults: Clinical Considerations By care.diabetesjournals.org Published On :: 2017-04-01 Pearl G. LeeApr 1, 2017; 40:444-452Emerging Science and Concepts for Management of Diabetes and Aging Full Article
ca The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study at 30 Years: Overview By care.diabetesjournals.org Published On :: 2014-01-01 David M. NathanJan 1, 2014; 37:9-16DCCT/EDIC 30th Anniversary Summary Findings Full Article
ca Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring By care.diabetesjournals.org Published On :: 2018-11-01 Richard M. BergenstalNov 1, 2018; 41:2275-2280Perspectives in Care Full Article
ca DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors By care.diabetesjournals.org Published On :: 2011-05-01 Dror DickerMay 1, 2011; 34:S276-S278Diabetes Treatments Full Article
ca Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability By care.diabetesjournals.org Published On :: 2011-05-01 Alan J. GarberMay 1, 2011; 34:S279-S284Diabetes Treatments Full Article
ca Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors Expert Forum By care.diabetesjournals.org Published On :: 2018-01-01 William T. CefaluJan 1, 2018; 41:14-31Diabetes Care Expert Forum Full Article
ca Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial By care.diabetesjournals.org Published On :: 2020-05-01 W. Timothy GarveyMay 1, 2020; 43:1085-1093Emerging Therapies: Drugs and Regimens Full Article
ca The Cost of Diabetes Care--An Elephant in the Room By care.diabetesjournals.org Published On :: 2018-05-01 Matthew C. RiddleMay 1, 2018; 41:929-932The Costs Of Diabetes Full Article
ca 2017 National Standards for Diabetes Self-Management Education and Support By care.diabetesjournals.org Published On :: 2017-10-01 Joni BeckOct 1, 2017; 40:1409-1419National Standards Full Article
ca Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association By care.diabetesjournals.org Published On :: 2016-12-01 Deborah Young-HymanDec 1, 2016; 39:2126-2140Psychosocial Research and Care in Diabetes Full Article
ca Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range By care.diabetesjournals.org Published On :: 2019-08-01 Tadej BattelinoAug 1, 2019; 42:1593-1603International Consensus Report Full Article
ca 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) By care.diabetesjournals.org Published On :: 2020-02-01 John B. BuseFeb 1, 2020; 43:487-493Consensus Report Update Full Article
ca Professional Practice Committee: Standards of Medical Care in Diabetes--2020 By care.diabetesjournals.org Published On :: 2020-01-01 Jan 1, 2020; 43:S3-S3Professional Practice Committee Full Article
ca Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes By care.diabetesjournals.org Published On :: 2020-01-20T12:00:30-08:00 OBJECTIVE To determine if the International Hypoglycaemia Study Group (IHSG) level 2 low glucose definition can identify clinically relevant hypoglycemia in clinical trials and offer value as an end point for future trials. RESEARCH DESIGN AND METHODS A post hoc analysis was performed of the SWITCH (SWITCH 1: n = 501, type 1 diabetes; SWITCH 2: n = 721, type 2 diabetes) and DEVOTE (n = 7,637, type 2 diabetes) trials utilizing the IHSG low glucose definitions. Patients in all trials were randomized to either insulin degludec or insulin glargine 100 units/mL. In the main analysis, the following definitions were compared: 1) American Diabetes Association (ADA) 2005 (plasma glucose [PG] confirmed ≤3.9 mmol/L with symptoms); and 2) IHSG level 2 (PG confirmed <3.0 mmol/L, independent of symptoms). RESULTS In SWITCH 2, the estimated rate ratios of hypoglycemic events indicated increasing differences between treatments with decreasing PG levels until 3.0 mmol/L, following which no additional treatment differences were observed. Similar results were observed for the SWITCH 1 trial. In SWITCH 2, the IHSG level 2 definition produced a rate ratio that was lower than the ADA 2005 definition. CONCLUSIONS The IHSG level 2 definition was validated in a series of clinical trials, demonstrating its ability to discriminate between basal insulins. This definition is therefore recommended to be uniformly adopted by regulatory bodies and used in future clinical trials. Full Article
ca Vasodilatory Actions of Glucagon-Like Peptide 1 Are Preserved in Skeletal and Cardiac Muscle Microvasculature but Not in Conduit Artery in Obese Humans With Vascular Insulin Resistance By care.diabetesjournals.org Published On :: 2020-02-20T11:55:30-08:00 OBJECTIVE Obesity is associated with microvascular insulin resistance, which is characterized by impaired insulin-mediated microvascular recruitment. Glucagon-like peptide 1 (GLP-1) recruits skeletal and cardiac muscle microvasculature, and this action is preserved in insulin-resistant rodents. We aimed to examine whether GLP-1 recruits microvasculature and improves the action of insulin in obese humans. RESEARCH DESIGN AND METHODS Fifteen obese adults received intravenous infusion of either saline or GLP-1 (1.2 pmol/kg/min) for 150 min with or without a euglycemic insulin clamp (1 mU/kg/min) superimposed over the last 120 min. Skeletal and cardiac muscle microvascular blood volume (MBV), flow velocity and blood flow, brachial artery diameter and blood flow, and pulse wave velocity (PWV) were determined. RESULTS Insulin failed to change MBV or flow in either skeletal or cardiac muscle, confirming the presence of microvascular insulin resistance. GLP-1 infusion alone increased MBV by ~30% and ~40% in skeletal and cardiac muscle, respectively, with no change in flow velocity, leading to a significant increase in microvascular blood flow in both skeletal and cardiac muscle. Superimposition of insulin to GLP-1 infusion did not further increase MBV or flow in either skeletal or cardiac muscle but raised the steady-state glucose infusion rate by ~20%. Insulin, GLP-1, and GLP-1 + insulin infusion did not alter brachial artery diameter and blood flow or PWV. The vasodilatory actions of GLP-1 are preserved in both skeletal and cardiac muscle microvasculature, which may contribute to improving metabolic insulin responses and cardiovascular outcomes. CONCLUSIONS In obese humans with microvascular insulin resistance, GLP-1’s vasodilatory actions are preserved in both skeletal and cardiac muscle microvasculature, which may contribute to improving metabolic insulin responses and cardiovascular outcomes. Full Article
ca Association of Urine Haptoglobin With Risk of All-Cause and Cause-Specific Mortality in Individuals With Type 2 Diabetes: A Transethnic Collaborative Work By care.diabetesjournals.org Published On :: 2020-02-20T11:55:30-08:00 OBJECTIVE Haptoglobin is an acute-phase reactant with pleiotropic functions. We aimed to study whether urine haptoglobin may predict risk of mortality in people with type 2 diabetes. RESEARCH DESIGN AND METHODS We employed a transethnic approach with a cohort of Asian origin (Singapore) (N = 2,061) and a cohort of European origin (France) (N = 1,438) included in the study. We used survival analyses to study the association of urine haptoglobin with risk of all-cause and cause-specific mortality. RESULTS A total of 365 and 525 deaths were registered in the Singapore cohort (median follow-up 7.5 years [interquartile range 3.5–12.8]) and French SURDIAGENE cohort (median follow-up 6.8 years [interquartile range 4.3–10.5], respectively. Singapore participants with urine haptoglobin in quartiles 2 to 4 had higher risk for all-cause mortality compared with quartile 1 (unadjusted hazard ratio [HR] 1.47 [95% CI 1.02–2.11], 2.28 [1.62–3.21], and 4.64 [3.39–6.35], respectively). The association remained significant in quartile 4 after multiple adjustments (1.68 [1.15–2.45]). Similarly, participants in the French cohort with haptoglobin in quartile 4 had significantly higher hazards for all-cause mortality compared with quartile 1 (unadjusted HR 2.67 [2.09–3.42] and adjusted HR 1.49 [1.14–1.96]). In both cohorts, participants in quartile 4 had a higher risk of mortality attributable to cardiovascular disease and infection but not malignant tumor. CONCLUSIONS Urine haptoglobin predicts risk of mortality independent of traditional risk factors, suggesting that it may potentially be a novel biomarker for risk of mortality in patients with type 2 diabetes. Full Article
ca A Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers: The TWO2 Study By care.diabetesjournals.org Published On :: 2020-02-20T11:55:30-08:00 OBJECTIVE Topical oxygen has been used for the treatment of chronic wounds for more than 50 years. Its effectiveness remains disputed due to the limited number of robust high-quality investigations. The aim of this study was to assess the efficacy of multimodality cyclical pressure Topical Wound Oxygen (TWO2) home care therapy in healing refractory diabetic foot ulcers (DFUs) that had failed to heal with standard of care (SOC) alone. RESEARCH DESIGN AND METHODS Patients with diabetes and chronic DFUs were randomized (double-blind) to either active TWO2 therapy or sham control therapy—both in addition to optimal SOC. The primary outcome was the percentage of ulcers in each group achieving 100% healing at 12 weeks. A group sequential design was used for the study with three predetermined analyses and hard stopping rules once 73, 146, and ultimately 220 patients completed the 12-week treatment phase. RESULTS At the first analysis point, the active TWO2 arm was found to be superior to the sham arm, with a closure rate of 41.7% compared with 13.5%. This difference in outcome produced an odds ratio (OR) of 4.57 (97.8% CI 1.19, 17.57), P = 0.010. After adjustment for University of Texas Classification (UTC) ulcer grade, the OR increased to 6.00 (97.8% CI 1.44, 24.93), P = 0.004. Cox proportional hazards modeling, also after adjustment for UTC grade, demonstrated >4.5 times the likelihood to heal DFUs over 12 weeks compared with the sham arm with a hazard ratio of 4.66 (97.8% CI 1.36, 15.98), P = 0.004. At 12 months postenrollment, 56% of active arm ulcers were closed compared with 27% of the sham arm ulcers (P = 0.013). CONCLUSIONS This sham-controlled, double-blind randomized controlled trial demonstrates that, at both 12 weeks and 12 months, adjunctive cyclical pressurized TWO2 therapy was superior in healing chronic DFUs compared with optimal SOC alone. Full Article
ca Time Course of Normalization of Functional {beta}-Cell Capacity in the Diabetes Remission Clinical Trial After Weight Loss in Type 2 Diabetes By care.diabetesjournals.org Published On :: 2020-03-20T11:50:34-07:00 OBJECTIVE To assess functional β-cell capacity in type 2 diabetes during 2 years of remission induced by dietary weight loss. RESEARCH DESIGN AND METHODS A Stepped Insulin Secretion Test with Arginine was used to quantify functional β-cell capacity by hyperglycemia and arginine stimulation. Thirty-nine of 57 participants initially achieved remission (HbA1c <6.5% [<48 mmol/mol] and fasting plasma glucose <7 mmol/L on no antidiabetic drug therapy) with a 16.4 ± 7.7 kg weight loss and were followed up with supportive advice on avoidance of weight regain. At 2 years, 20 participants remained in remission in the study. A nondiabetic control (NDC) group, matched for age, sex, and weight after weight loss with the intervention group, was studied once. RESULTS During remission, median (interquartile range) maximal rate of insulin secretion increased from 581 (480–811) pmol/min/m2 at baseline to 736 (542–998) pmol/min/m2 at 5 months, 942 (565–1,240) pmol/min/m2 at 12 months (P = 0.028 from baseline), and 936 (635–1,435) pmol/min/m2 at 24 months (P = 0.023 from baseline; n = 20 of 39 of those initially in remission). This was comparable to the NDC group (1,016 [857–1,507] pmol/min/m2) by 12 (P = 0.064) and 24 (P = 0.244) months. Median first-phase insulin response increased from baseline to 5 months (42 [4–67] to 107 [59–163] pmol/min/m2; P < 0.0001) and then remained stable at 12 and 24 months (110 [59–201] and 125 [65–166] pmol/min/m2, respectively; P < 0.0001 vs. baseline) but lower than that of the NDC group (250 [226–429] pmol/min/m2; P < 0.0001). CONCLUSIONS A gradual increase in assessed functional β-cell capacity occurred after weight loss, becoming similar to that of NDC group participants by 12 months. This result was unchanged at 2 years with continuing remission of type 2 diabetes. Full Article
ca Mexican Immigrants in the United States By www.migrationpolicy.org Published On :: Fri, 05 Oct 2018 12:11:43 -0400 For decades, Mexicans have been the largest immigrant group in the United States. While this is still the case, the Mexican immigrant population is no longer growing at the rate it once was. In fact, between 2010 and 2017, the number of Mexicans in the country first leveled off and then began to decline. This article explores the latest data on Mexican immigrants in the United States. Full Article
ca South American Immigrants in the United States By www.migrationpolicy.org Published On :: Tue, 06 Nov 2018 17:46:12 -0500 South Americans represent a small, but growing share of immigrants in the United States, composing 7 percent of country’s total foreign-born population. Recent growth has been marked by an uptick in arrivals from increasingly failing Venezuela, with an increase of 61,000 Venezuelan immigrants from 2016 to 2017. This article offers an interesting data snapshot of South American immigrants in the United States. Full Article
ca Caribbean Immigrants in the United States By www.migrationpolicy.org Published On :: Tue, 12 Feb 2019 15:31:55 -0500 Caribbean immigrants represent 10 percent of the 44.5 million immigrants in the United States, with the vast majority coming from just five countries: Cuba, the Dominican Republic, Jamaica, Haiti, and Trinidad and Tobago. Depending on their origin country and period of arrival, immigrants from the Caribbean have varying skill levels, racial composition, language background, and motivations for migration, as this article explores. Full Article
ca Central American Immigrants in the United States By www.migrationpolicy.org Published On :: Mon, 12 Aug 2019 11:16:49 -0400 While much attention has been paid to recent Central American arrivals at the U.S.-Mexico border, nearly half of the approximately 3.5 million Central Americans resident in the United States in 2017 arrived before 2000. About one-third are naturalized U.S. citizens, and they tend to participate in the labor force at a higher rate than foreign- and U.S.-born adults. Discover more about this population in this data-rich article. Full Article
ca Inmigrantes centroamericanos en los Estados Unidos By www.migrationpolicy.org Published On :: Mon, 12 Aug 2019 12:58:39 -0400 Si bien se ha prestado mucha atención a los centroamericanos recién llegados a la frontera entre los Estados Unidos y México, casi la mitad de los aproximadamente 3.5 millones que vivían en los Estados Unidos en 2017 llegaron antes de 2000. Aproximadamente un tercio son ciudadanos estadounidenses y tienden a participar en la fuerza laboral con más frecuencia que otros extranjeros y estadounidenses. Descubra más en este artículo lleno de datos. Full Article
ca Sub-Saharan African Immigrants in the United States By www.migrationpolicy.org Published On :: Tue, 05 Nov 2019 11:55:03 -0500 The sub-Saharan African immigrant population in the United States is a small, but quickly growing, one. Between 2010 and 2018, the size of the sub-Saharan African population increased 52 percent, far outpacing the overall rise in the foreign born. Immigrants coming from the 51 sub-Saharan countries, including Nigeria, Ghana, Ethiopia, and Somalia, are diverse in their origins and socioeconomic characteristics, as this Spotlight explores. Full Article
ca As COVID-19 Slows Human Mobility, Can the Global Compact for Migration Meet the Test for a Changed Era? By www.migrationpolicy.org Published On :: Mon, 27 Apr 2020 16:05:08 -0400 The coronavirus pandemic dramatically reshaped how human mobility is managed just as the Global Compact for Safe, Orderly, and Regular Migration was beginning to move from paper to implementation. As governments face pressing public-health, economic, and other concerns in responding to COVID-19, this MPI Europe commentary explores whether the first comprehensive global agreement on migration can adjust to a changed reality. Full Article
